Back to dashboard
CommercialCoverageMedium impact

08.02.49, Pembrolizumab and berahyaluronidase alfa-pmph (Keytruda QLEX™)

Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Feb 2, 2026
We identified it
Jun 19, 2026
Days to comply
—

Summary

A new policy for Pembrolizumab and berahyaluronidase alfa-pmph (Keytruda QLEX™) has been established effective February 2, 2026. This is a pharmacy policy for a combination cancer immunotherapy drug that will require specific coverage guidelines and billing procedures.

Action Required

Action needed
Before February 2, 2026: Billing team must review the full policy details at the provided URL to understand coverage criteria, prior authorization requirements, and billing procedures for Keytruda QLEX™. Update pharmacy billing protocols and inform oncology providers of new policy requirements.

Related policy hubs